Company: ANIX
Filing Date: 2025-05-28
Form Type: 10-Q
Source: 0001641172-25-012701
Chunk: 14

Company: Anixa Biosciences Inc
Filing Date: 2025-05-28
Form: 10-Q
Item: Part I, Item 8
Chunk 14
---
496 

The following table presents the
hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2024 (in thousands):

    Level 1  
    Level 2  
    Level 3  
    Total 
  
    Money market funds: 

    Cash equivalents 
    $1,170  
    $-  
    $-  
    $1,170 
  
    U.S. treasury bills: 

    Short-term investments 
     -  
     18,653  
     -  
     18,653 
  
    Total financial assets 
    $1,170  
    $18,653  
    $-  
    $19,823 

Our non-financial assets that
are measured at fair value on a non-recurring basis are property and equipment and other assets which are measured using fair value techniques
whenever events or changes in circumstances indicate a condition of impairment exists. The estimated fair value of prepaid expenses and
other current assets, accounts payable and accrued expenses approximates their individual carrying amounts due to the short-term nature
of these measurements. Cash equivalents are stated at carrying value which approximates fair value.

    13

5. ACCRUED EXPENSES

Accrued expenses consist of the
following as of:

 SCHEDULE OF ACCRUED EXPENSES

    April 30,  
    October 31, 

    2025  
    2024 

    (in thousands) 
  
    Payroll and related expenses 
    $721  
    $1,126 
  
    Accrued royalty and contingent legal fees 
     626  
     626 
  
    Accrued other 
     219  
     194 
  
    Accrued expenses 
    $1,566  
    $1,946 

6. NET LOSS PER SHARE OF COMMON STOCK

Basic net loss per common share
(“Basic EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss
per common share (“Diluted EPS”) is computed by dividing net loss by the weighted average number of common shares and dilutive
common share equivalents and convertible securities then outstanding. Diluted EPS for all periods presented is the same as Basic EPS,
as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive